Vol. 1 No. 11 (2021)
Reimbursement Recommendations

Pembrolizumab (Keytruda)

Published November 1, 2021

Key Messages

  • CADTH recommends that Keytruda should be reimbursed by public drug plans for the treatment of adult and pediatric patients with refractory or relapsed classical Hodgkin lymphoma (cHL) if certain conditions are met.
  • Keytruda should only be reimbursed to treat patients who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.
  • Keytruda should only be reimbursed as monotherapy and if the cost of pembrolizumab is reduced.